Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes
Cancers · 20.04.2023 · 15 (8) · 2383
DOI: 10.3390/cancers15082383 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 20.04.2023. Verfasst von Mefotse Saha Cyrelle Ornella und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research institute for Convergence of biomedical science and technology, Pusan National University Yangsan Hospital.
Abstract (Originalsprache)
Peritoneal metastasis, also known as peritoneal carcinomatosis (PC), is a refractory cancer that is typically resistant to conventional therapies. The typical treatment for PC is a combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Recently, research in this area has seen significant advances, particularly in immunotherapy as an alternative therapy for PC, which is very encouraging. Catumaxomab is a trifunctional antibody intraperitoneal (IP) immunotherapy authorized in Europe that can be used to diminish malignant ascites by targeting EpCAM. Intraperitoneal (IP) immunotherapy breaks immunological tolerance to treat peritoneal illness. Increasing T-cell responses and vaccination against tumor-associated antigens are two methods of treatment. CAR-T cells, vaccine-based therapeutics, dendritic cells (DCs) in combination with pro-inflammatory cytokines and NKs, adoptive cell transfer, and immune checkpoint inhibitors are promising treatments for PC. Carcinoembryonic antigen-expressing tumors are suppressed by IP administration of CAR-T cells. This reaction was strengthened by anti-PD-L1 or anti-Gr1. When paired with CD137 co-stimulatory signaling, CAR-T cells for folate receptor cancers made it easier for T-cell tumors to find their way to and stay alive in the body.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea.
- Bionoxx Inc., Parkview Tower #1905, 248 Jeongjail-ro, Bundang-gu, Seongnam 13554, Republic of Korea.
- Division of Hematology & Oncology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea.
ORCID-Profile: Narayanasamy Badrinath, Jae-Joon Kim
Förderung
- Research institute for Convergence of biomedical science and technology, Pusan National University Yangsan Hospital
Zitieren
APA
Ornella, M. S. C., Badrinath, N., Kim, K. A., Kim, J. H., Cho, E., Hwang, T. H., & Kim, J. J. (2023). Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes. Cancers, 15(8), 2383. https://doi.org/10.3390/cancers15082383
Vancouver
Ornella MSC, Badrinath N, Kim KA, Kim JH, Cho E, Hwang TH, et al. Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes. Cancers. 2023;15(8):2383. doi:10.3390/cancers15082383
BibTeX
@article{Ornella2023,
author = {Ornella, Mefotse Saha Cyrelle and Badrinath, Narayanasamy and Kim, Kyeong-Ae and Kim, Jung Hee and Cho, Euna and Hwang, Tae-Ho and Kim, Jae-Joon},
title = {Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes},
journal = {Cancers},
year = {2023},
volume = {15},
number = {8},
pages = {2383},
doi = {10.3390/cancers15082383}
}
EUVIMED